Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kewaunee Scientific Corporation’s (NASDAQ: KEQU) SEC filings, allowing investors and researchers to review the company’s official regulatory disclosures. Kewaunee files reports and current event disclosures with the U.S. Securities and Exchange Commission as a public company listed on The Nasdaq Global Market.
In these filings, users can find quarterly and annual financial information, including discussions of segment performance for the domestic, international, and corporate segments. The company also explains its use of non-GAAP measures such as EBITDA, Segment EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share, and provides reconciliations to the most comparable GAAP measures.
Kewaunee’s Form 8-K current reports cover topics such as quarterly and annual results, amendments to bylaws, board appointments, annual meeting outcomes, and the timing of earnings releases. Proxy materials, such as the company’s definitive proxy statement, describe matters submitted to shareholders, including director elections, auditor ratification, advisory votes on executive compensation, and the frequency of such advisory votes.
Filings also document capital markets and governance actions, including details of share repurchase program approvals or amendments, loan agreements and related disclosures, and information about non-employee director compensation and committee assignments. Together, these documents provide a structured view of Kewaunee’s financial condition, governance framework, and significant corporate events.
On Stock Titan, KEQU filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered summaries highlight key points from long-form documents, helping users quickly understand the main changes, financial metrics, and governance decisions without reading every page of each filing.
Kewaunee Scientific announced the appointment of Mr. Campbell to its Board and approved amended bylaws. Mr. Campbell brings extensive finance and restructuring experience from roles at Carl Marks Advisors and prior executive positions at Griffin LLC, PepsiCo and Frito-Lay, and is a certified public accountant with decades in public accounting and corporate finance. The Board determined he meets Nasdaq and SEC independence and financial literacy requirements and has named him to the Audit Committee.
The company said Mr. Campbell will be paid under the standard non-employee director program and will receive a pro-rated equity grant for fiscal 2026. The Board also amended Section 5.02 of the Bylaws to set the Board size at a minimum of five and maximum of nine directors, with the exact number fixed by Board resolution.
Kewaunee Scientific Corporation filed a current report to let investors know it has released financial results for the first quarter of its fiscal year 2026. The company states that these results were announced in a press release dated September 10, 2025, which is provided as Exhibit 99.1.
The report explains that this press release is being furnished, rather than filed, which limits how it is treated under securities laws. Kewaunee’s common stock continues to trade on the Nasdaq Global Market under the symbol KEQU.
Kewaunee Scientific Corporation reported the results of its Annual Meeting of Shareholders held on August 27, 2025. Shareholders re-elected Class III directors Margaret B. Pyle and Donald F. Shaw, with Pyle receiving 1,633,067 votes for and 189,229 withheld, and Shaw receiving 1,730,171 votes for and 92,125 withheld, along with 537,449 broker non-votes for each nominee.
Shareholders ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal 2026, with 2,356,636 votes for, 2,119 against, and 990 abstentions. On an advisory basis, shareholders approved the compensation of the named executive officers with 1,448,991 votes for, 103,177 against, 270,128 abstentions, and 537,449 non-votes.
In an advisory vote on the frequency of future say-on-pay votes, shareholders favored holding the vote every one year, with 1,512,884 votes for one year, 1,194 for two years, 306,985 for three years, 1,233 abstentions, and 537,449 non-votes. The company will include an annual non-binding advisory vote on executive compensation in its proxy materials consistent with this outcome and the Board’s recommendation.
Kewaunee Scientific Corporation filed a current report to let investors know when it will share its next results. The company announced that it plans to release its first quarter fiscal 2026 earnings on September 10, 2025. This update is provided through a press release that is attached to the report as an exhibit and incorporated by reference.
Kewaunee Scientific Corporation furnished an investor presentation and related script in connection with its virtual Annual Meeting of Shareholders held at 11:00 a.m. Eastern time on August 27, 2025. These materials, attached as Exhibits 99.1 and 99.2, are also available in the Investor Information section of the company’s website and a replay of the audio webcast of the meeting will remain accessible for about one year. The company uses non-GAAP financial measures in the presentation and provides reconciliations to comparable GAAP measures in the same location. The materials also include forward-looking statements, and the company points investors to its Form 10-K for the year ended April 30, 2025 and other SEC filings for a discussion of risk factors that could cause actual results to differ.
Kewaunee Scientific Corp. (KEQU) – Form 4 filed 07/28/2025 reports two open-market sales by CFO Donald T. Gardner III on 07/24/2025.
- Sold 2,096 common shares at a weighted avg. $58.34 (range $58.00-$58.97).
- Sold 904 common shares at a weighted avg. $59.18 (range $59.00-$59.45).
- Total shares sold: 3,000; estimated proceeds ≈ $175k.
- Direct ownership dropped from 17,564 to 14,564 shares, a reduction of roughly 17%.
No derivative transactions were reported and the filing offers no commentary on the purpose of the sales.
Kewaunee Scientific Corp. (KEQU) – Form 144 filing: an unidentified insider intends to sell up to 3,000 common shares through Fidelity Brokerage Services on or about 07/23/2025 via Nasdaq. At the recent reference price, the proposed sale is valued at $174,750.
The company has 2,844,290 shares outstanding, so the sale represents roughly 0.1 % of total shares. The seller acquired the stock on 06/23/2023 as a stock-award compensation; no cash purchase was involved, and there have been no other sales in the past three months. The filer certifies that no non-public, material adverse information is known.
While Form 144 notices are routine, any insider disposition can influence sentiment. Given the small size relative to float and absence of other sales, the filing is unlikely to be materially impactful for KEQU’s fundamentals.